1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Ravulizumab, Pozelimab, Cemdisiran - Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Active not recruiting | Regeneron Pharmaceuticals | 202 | 2022-08-01 | 2026-04-30 |
Hemoglobinuria, Paroxysmal (1)
Brazil (1) · Canada (1) · China (1) · Colombia (1) · Greece (1) · Hungary (1) · India (1) · Italy (1) · Japan (1) · Jordan (1) · Malaysia (1) · Mexico (1) · Peru (1) · Philippines (1) · Poland (1)
2023 (1)